Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Cost Reimbursement
Drugs
Locations
Clinical Specialty
521-540 of 991 trials

GEN1047 for Solid Tumors - First in Human Trial

We are testing a new treatment called GEN1047 for people with malignant solid tumors. The study aims to find the safest dose and evaluate how well it works against cancer.

Malignant Solid Tumors6-12 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Hidradenitis Suppurativa: Lutikizumab Study

We are evaluating the effectiveness and safety of lutikizumab for treating moderate to severe hidradenitis suppurativa in adults and adolescents. This study compares lutikizumab to a placebo to see how well it works.

Hidradenitis Suppurativa1-2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementDermatology

Knee Osteoarthritis: Diclofenac vs. Placebo

We are studying how diclofenac affects knee pain compared to a placebo in people with knee osteoarthritis. The trial also looks at how a special script may change patients' pain experiences.

Knee Osteoarthritis≤3 monthsMonitoring phase (IV)≤5 visitsStandard MedicinesCost ReimbursementInternal MedicineOrthopedics and Traumatology

Metastatic Non-Small-Cell Lung Cancer: LN-145 Treatment Study

We are investigating whether LN-145, a type of immune cell therapy, is safe and effective for patients with metastatic non-small-cell lung cancer. The study will assess how well it works in shrinking tumors and improving patient outcomes.

Metastatic Non-Small-Cell Lung CancerEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Ulcerative Colitis: CICR-NAM Treatment Study

We are testing a new oral medication for people with mild to moderately active ulcerative colitis. The goal is to see if it helps improve symptoms and overall gut health.

Ulcerative Colitis1-2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementGastroenterology

Prolonged Seizures: Staccato Alprazolam Study

We are investigating whether Staccato Alprazolam is safe and effective for quickly stopping prolonged seizures in individuals aged 12 and older. The study compares its effects to a placebo to assess its benefits.

Prolonged Seizure3-6 monthsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteNeurology

Diffuse Large B-Cell Lymphoma: Epcoritamab Plus Lenalidomide

We are studying whether a new combination of epcoritamab and lenalidomide can improve survival rates for adults with relapsed or refractory diffuse large B-cell lymphoma compared to standard treatments.

Relapsed or Refractory Diffuse Large B-Cell Lymphoma6-12 monthsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology

Mucopolysaccharidosis Type II: DNL310 vs Idursulfase

We are studying a new treatment, DNL310, for children and young adults with Mucopolysaccharidosis Type II to see if it works better than the current treatment, Idursulfase, in improving brain and physical health.

Hunter's Syndrome>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementHematologyNeurology

Chronic Kidney Disease: BI 690517 with Empagliflozin

We are studying whether a new daily pill can help prevent worsening kidney disease and heart problems in people with chronic kidney disease. Participants will compare this treatment to a placebo to see its effects.

Chronic Kidney Disease>2 yearsConfirmation phase (III)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyNephrology

Advanced Prostate Cancer: Debio 4228 Study

We are testing a new medication, Debio 4228, to see if it effectively lowers hormone levels in men with advanced prostate cancer. The study will also look at how well the medication is tolerated and its safety profile.

Advanced Prostate Cancer6-12 monthsEfficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncologyUrology

Ovarian and Lung Cancer: TUB-040 Treatment Study

We are investigating a new antibody-guided drug for patients with therapy-resistant ovarian or lung cancer. The study aims to assess its safety and how well it works compared to existing treatments.

Platinum-Resistant High-Grade Ovarian Cancer and Non-Small Cell Lung CancerSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementGynecology and ObstetricsOncologyPulmonology

Denosumab for Fibrous Dysplasia and McCune-Albright Syndrome

We are studying whether Denosumab can help reduce pain and improve quality of life for adults with Fibrous Dysplasia and McCune-Albright Syndrome. The trial will also look at its effects on mobility and bone health.

Fibrous Dysplasia/McCune-Albright Syndrome1-2 yearsConfirmation phase (III)Monitoring phase (IV)≤5 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementEndocrinologyOrthopedics and Traumatology

Myotonic Dystrophy: Long-Term Study of Mexiletine PR

We are examining the long-term safety and effectiveness of mexiletine PR for treating myotonia in patients with myotonic dystrophy types 1 and 2. This study is for those who have completed a prior related study.

Myotonic Dystrophy1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineNeurology

Myotonic Dystrophy: Mexiletine PR Study

We are investigating whether once daily mexiletine can help reduce muscle stiffness in patients with myotonic dystrophy types 1 and 2. The study will also look at its safety and how it affects daily activities.

Myotonic Dystrophy6-12 monthsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementNeurology

Multiple Myeloma: Anitocabtagene Autoleucel Study

We are comparing a new treatment called anitocabtagene autoleucel with standard therapies for patients with relapsed or refractory multiple myeloma. The goal is to see which option works better and is safer for patients.

Relapsed/Refractory Multiple MyelomaConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

HIV Treatment: Combination Therapy Study

We are investigating a combination of three drugs to see if they can help reactivate HIV in people living with the virus. This study aims to understand the safety and effectiveness of these treatments.

HIV-1≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteInfectious DiseasesInternal Medicine

Celiac Disease: Amlitelimab Treatment Study

We are investigating whether amlitelimab can help adults with non-responsive celiac disease improve their symptoms and intestinal health while on a gluten-free diet. The study also examines the safety of this new treatment.

Coeliac Disease6-12 monthsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterology

Non-Small Cell Lung Cancer: Alectinib and Chemotherapy Study

We are investigating how well alectinib combined with chemotherapy works for patients with early-stage non-small cell lung cancer. This study focuses on those whose cancer can be surgically removed and who have specific biomarker characteristics.

Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Atopic Dermatitis: APG777 Treatment Study

We are studying a new treatment called APG777 for people with moderate-to-severe atopic dermatitis. The goal is to see if it helps reduce symptoms like itching and skin pain compared to a placebo.

Atopic Dermatitis>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Blood Cancer: Long-term Study of Zanubrutinib

We are evaluating the long-term safety and effectiveness of Zanubrutinib in patients with B-cell malignancies. This study is for those who have previously participated in a related trial.

B-cell Lymphoma>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology